Navigation Links
XTENT Announces Promising Six-Month Custom II Trial Data Presented,at EuroPCR Meeting

n the second half of 2007.

CUSTOM II webcast and slide presentation

XTENT will host a webcast, slide presentation and telebriefing to review the CUSTOM II data Tuesday, May 22 at 2:00p.m. EDT (at 8:00p.m. CEST). The teleconference and slide presentation can be accessed via the investor relations section of the Company's website at http://investor.xtentinc.com/events.cfm or by calling 800-361-0912 (from the U.S.), 913-981-5559 (international). Please dial in or access the website 5 to 10 minutes prior to the beginning of the call. The webcast will be archived on the website for a minimum of three months, and can be accessed at the investor relations portion of the company's website at http://investor.xtentinc.com

About XTENT

XTENT, Inc. is a medical device company focused on developing and commercializing innovative customizable drug eluting stent (DES) systems for the treatment of coronary artery disease (CAD). CAD is the most common form of cardiovascular disease and the number one cause of death in the United States and Europe. XTENT(R) Custom NX(R) DES Systems are designed to enable the treatment of single lesions, long lesions and multiple lesions of varying lengths and diameters, in one or more arteries with a single device. Note: XTENT(R) Custom NX(R) DES Systems have not been approved for sale by any regulatory authority.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this press release regarding XTENT's business that are not historical facts may be "forward-looking statements" that involve risks and uncertainties. Specifically, these statements include, but are not limited to those concerning: XTENT's ability to initiate its U.S. pivotal trial in the second ha
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product

Post Your Comments:
(Date:11/6/2009)...e-USNewswire/ -- The ,Help is Here Express, bus to...throughout the week of November 9-13 at various ci...ruggling patients access information on programs t...rly free. With the nation,s unemployment rate now ...tion Assistance (PPA) bus tour is raising awarenes...
(Date:11/6/2009)...stCall/ -- Boston Scientific Corporation (NYSE: B...ent in principle with the U.S. Department of Justi...ts Guidant subsidiary in 2005. The alleged conduc...tific,s 2006 acquisition of Guidant. ,, Boston ...on by the U.S. Attorney,s Office in Minneapolis in...
(Date:11/6/2009)...l/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KER...er 10, 2009 at 8:30 a.m. EST to discuss the third ...k for the remainder of 2009. Ron Bentsur, Chief E...l. Keryx will announce its financial results for ...to the call. ,, In order to participate in the ...
Breaking Medicine Technology:Partnership for Prescription Assistance Prepared to Help Southern Workers Hurt by Recession 2Partnership for Prescription Assistance Prepared to Help Southern Workers Hurt by Recession 3Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 2Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 3Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 4Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 5Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 6Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 7Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 8Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 9Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 10Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 11Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 12Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 13Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 14Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 15Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 16Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 17Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2009 Financial Results on Tuesday, November 10, 2009 at 8:30 a.m. EST 2Twelve Going on 70 3A SCAN Health Plan Arizona Helps 7th and 8th Graders Understand Aging With Senior Sensitivity Training 58203 1Twelve Going on 70 3A SCAN Health Plan Arizona Helps 7th and 8th Graders Understand Aging With Senior Sensitivity Training 58203 2The Dr Oz Show and the National Football League Join Forces as 20 Moms of NFL Players Go Head to Head to Improve Their Health in DR OZS ULTIMATE HEA 58199 1The Dr Oz Show and the National Football League Join Forces as 20 Moms of NFL Players Go Head to Head to Improve Their Health in DR OZS ULTIMATE HEA 58199 2The Dr Oz Show and the National Football League Join Forces as 20 Moms of NFL Players Go Head to Head to Improve Their Health in DR OZS ULTIMATE HEA 58199 3Abbotts XIENCE V 28R 29 Demonstrates Significantly Lower Rates of MACE and Stent Thrombosis Compared to TAXUS 28R 29 Liberte in Investigator Initiated 5042 1Abbotts XIENCE V 28R 29 Demonstrates Significantly Lower Rates of MACE and Stent Thrombosis Compared to TAXUS 28R 29 Liberte in Investigator Initiated 5042 2Abbotts XIENCE V 28R 29 Demonstrates Significantly Lower Rates of MACE and Stent Thrombosis Compared to TAXUS 28R 29 Liberte in Investigator Initiated 5042 3
...ers identify molecular signature in human type 1 d...dren,s Research,Institute, located in Milwaukee, r...iabetes diagnosis. Led by Martin Hessner, PhD, ass...e research team applied a new,approach, finding th...hase,create a unique genomic fingerprint. The rese...
...ESVILLE, Va., April 16 The,Foundation for Cancer ...,prostate cancer oncologist and survivor, Dr. Char... for prostate cancer at Westminster at Lake Ridge,...th the recent press around prostate cancer vaccine...Myers says. "The good news is there are many,thing...
Other Medicine Technology:Discovery Leads to Earlier Diagnosis of Type 1 Diabetes 2Free Prostate Cancer Seminar in Lake Ridge, VA: Dr. Charles 'Snuffy' Myers Announces Vitamin D Clinical Trials 2
(Date:11/8/2009)...hing Taxes Nail Nation,s Job Creators ,, WASHIN...e to U.S. House passage of the health care bill (H...ouncil (SBE Council) president & CEO Karen Ker... no mistake, those voting for H.R. 3962 voted to b...and crushing taxes and penalties. Even in the best...
(Date:11/8/2009)...RNewswire-USNewswire/ -- Tonight the House of Repr...America Act, landmark health reform legislation th...y, affordable, stable and secure health care cover... the insurance industry,s worst practices, would e... deficit by $104 billion over ten years. Groups re...
(Date:11/8/2009)...D Global Solutions is pleased to announce that it ...al effort for ReSound who recently received an awa...ract. The award includes not only the Veterans Adm...d other federal agencies. , ...bal Solutions is pleased to announce that it has b...
(Date:11/8/2009)...en’s Health Network (MHN) urges military vet...y those linked to exposure to chemicals, atomic ag...der cancer is one of those cancers that is two tim...o once smoked or currently smoke cigarettes. , ...er 8, 2009 -- Men’s Health Network (MHN) kic...
(Date:11/8/2009)...RNewswire-USNewswire/ -- Today, the House of Repre...emper, Smith, Ellsworth and Lipinski amendment to ... 3962). The amendment maintains the current policy...r benefits packages that include abortion. It clar...ordability credits and those who do not, can with ...
Breaking Medicine News(10 mins):Health News:Democratic National Committee Chairman Tim Kaine Issues Statement Praising the House of Representative's Historic Vote to Pass Health Insurance Reform 2Health News:Democratic National Committee Chairman Tim Kaine Issues Statement Praising the House of Representative's Historic Vote to Pass Health Insurance Reform 3Health News:3D Global Solutions Selected to Program Manage GN ReSound/VA Digital Hearing Aid Contract 2Health News:3D Global Solutions Selected to Program Manage GN ReSound/VA Digital Hearing Aid Contract 3Health News:Veterans' Day Reminder from Men's Health Network: Pay Attention to Bladder Cancer Symptoms and Risk Factors 2Health News:Veterans' Day Reminder from Men's Health Network: Pay Attention to Bladder Cancer Symptoms and Risk Factors 3Health News:Family Research Council Praises Passage of Pro-life Amendment to Health Care Bill 2
...aphy or PET scans can help clinicians diagnose and...er the imaging technology helps people with cancer...omprehensive review by the U.K. National Health Se... imaging technologies such as computerized tomogra...
... Beckman Coulter,Inc. (NYSE: BEC ), a leading dev...t simplify, automate, and innovate complex biomedi...eckman Coulter,s senior vice,president and chief f...p://www.newscom.com/cgi-bin/prnh/20031202/BECLOGO ...
...COUVER, Nov. 12 /PRNewswire-FirstCall/ - Cardiome ...nced that it will report 2007 third,quarter financ...13, 2007.,Cardiome will hold a teleconference call... or,866-540-8136. There will be a separate dial-in...
...ke the New Lower-Strength lopinavir/ritonavir,Tabl... Broad Access for the More Than 2 Million ...Ill., Nov. 12 Abbott today,announced that it has ...) (lopinavir/ritonavir), which is also,marketed as...
...ay announced the Middle East launch of the Arabic ...ntinuous Glucose Monitoring System (Paradigm REAL-...s who use insulin to treat diabetes. It is the fir...ecisions to improve their glucose control after co...
... biologists at Jeffersons Kimmel Cancer Center in ... events behind some potentially dangerous autoinfl... gained a greater understanding of the disease pro...mad Alnemri, Ph.D., professor of Biochemistry and ...
Other Medicine News:Health News:PET scans useful for some cancer treatment, but how do patients fare? 2Health News:Beckman Coulter to Present at the Credit Suisse Global Healthcare Conference 2Health News:Cardiome To Release Third Quarter Results 2Health News:Cardiome To Release Third Quarter Results 3Health News:Abbott Receives U.S. Food and Drug Administration Approval for New Lower-Strength Kaletra(R) (lopinavir/ritonavir) Tablet for Pediatric HIV Patients 2Health News:Abbott Receives U.S. Food and Drug Administration Approval for New Lower-Strength Kaletra(R) (lopinavir/ritonavir) Tablet for Pediatric HIV Patients 3Health News:Abbott Receives U.S. Food and Drug Administration Approval for New Lower-Strength Kaletra(R) (lopinavir/ritonavir) Tablet for Pediatric HIV Patients 4Health News:Abbott Receives U.S. Food and Drug Administration Approval for New Lower-Strength Kaletra(R) (lopinavir/ritonavir) Tablet for Pediatric HIV Patients 5Health News:Abbott Receives U.S. Food and Drug Administration Approval for New Lower-Strength Kaletra(R) (lopinavir/ritonavir) Tablet for Pediatric HIV Patients 6Health News:Jefferson scientists uncover key pathway, potential drug targets in autoinflammatory disease 2
...harmDx Kit is a direct fluorescence in situ hybrid...termine HER2 gene amplification in formalin-fixed,... Gene amplification is determined from the ratio b...n of the HER2 gene probe (red signals) and the num...
...is the only HER-2 assessment test approved by the ...laims: prognosis, adriamycin-based chemotherapy se...l antibody therapy selection. PathVysion is the on...erceptin® package insert as an appropriate tes...
...in Anesthesia and Respiratory Products, ,Westmed ... medical devices for Anesthesia and Respiratory pr...ure products that enhance the clinician's ability ... attention to the bottom line. , ,Our web site is...
...livers breakthrough continuous low-flow nebulizer ...se nozzle technology allows for optimal medication... OMNI~NEB takes on severe asthma, COPD and pneumon...onfigure with a mask, mouth and T-piece to deliver...
Medicine Products: